Search | Clinical Trials Finder

Conditions: Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking (CXL); Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: Keratitis
Interventions: B+L Biotrue MPS and B+L PureVision; Device
Lead sponsor: Epstein, Arthur B., OD, FAAO; Individual
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Corneal Opacity, Keratoconus
Interventions: LALAK, IEK, Retrobulbar Block or General Anesthesia, optical coherence tomography (OCT), Topical Anesthesia, femtosecond laser; Procedure · Drug · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Trichiasis
Interventions: TT Training Program and TT Screening Card; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years and older
Enrollment: 27,473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Astigmatism
Interventions: Astigmatic Correction Lens (Nexis ACCL lenses), Toric Soft Contact Lenses; Device
Lead sponsor: FORSIGHT Vision3; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 6
States / cities: Fremont, California • Livermore, California • Menlo Park, California + 2 more

Conditions: Keratoconus, Irregular Astigmatism, Corneal Ectasia, Aberration, Corneal Wavefront, Wavefront Aberration, Corneal, Pellucid Marginal Corneal Degeneration, Keratoglobus
Interventions: Wavefront Guided Scleral Lenses, Traditional Scleral Lenses; Device
Lead sponsor: Cornea and Laser Eye Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Keratoconus, Corneal Ectasia
Interventions: Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2; Drug · Device
Lead sponsor: Robert Mack, M.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Hoffman Estates, Illinois

Conditions: Cataracts
Interventions: Standard phacoemulsification, Reduced ultrasound phacoemulsification; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: pegaptanib sodium injection; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Keratoconus, Ectasia, Degeneration
Interventions: Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.); Drug
Lead sponsor: Cxlusa; Industry
Eligibility: 8 Years and older
Enrollment: 1,189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 3
States / cities: Miami, Florida • Rockville, Maryland • Fairfax, Virginia

Conditions: Keratoconus, Corneal Ectasia
Interventions: Riboflavin/Dextran, Hypotonic Riboflavin; Drug
Lead sponsor: Cornea and Laser Eye Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Blepharitis, Conjunctivitis, Corneal Disease, Dacryoadenitis, Dacryocystitis, Keratitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Corneal Neovascularization
Interventions: Subconjunctival aflibercept, Placebo: Standard of care only; Drug · Other
Lead sponsor: Balamurali Ambati; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Corneal Opacity
Interventions: Mitomycin-C, Fluorometholone 1% topical ocular steroid; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy
Interventions: endothelial keratoplasty; Procedure
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Enrollment: 2,593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cataracts
Interventions: Femtosecond Laser; Procedure
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Goodlettsville, Tennessee

Conditions: Aniridia
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 4 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Cincinnati, Ohio

Conditions: Corneal Diseases, Cornea Transplant
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Dry Eye Disease (DED)
Interventions: 3% trehalose; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Cataract, Dry Eye
Interventions: Not listed
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Rockville Centre, New York

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more

Search by objective public record fields.

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

OCT-guided LALAK for KCN

Identification of TT Cases by Community Treatment Assistants: An Assessment

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Evaluation Study on Corneal Lens for Vision Correction

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

Endothelial Cell Loss After Cataract Surgery

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

Evaluation and Treatment of Patients With Corneal and External Diseases

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

Nephrotic Syndrome Study Network

Study of Endothelial Keratoplasty Outcomes

Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery

Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)